Cargando…

New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib

Janus kinases (JAK) are a family of tyrosine kinases (JAK1, JAK2, JAK3, and TYK2) that transduce cytokine-mediated signals through the JAK–STAT metabolic pathway. These kinases act by regulating the transcription of specific genes capable of inducing biological responses in several immune cell subse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marcuzzi, Annalisa, Rimondi, Erika, Melloni, Elisabetta, Gonelli, Arianna, Grasso, Antonio Giacomo, Barbi, Egidio, Maximova, Natalia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955311/ https://www.ncbi.nlm.nih.gov/pubmed/35337171 http://dx.doi.org/10.3390/ph15030374

Ejemplares similares

Mitochondria-Targeted Antioxidants, an Innovative Class of Antioxidant Compounds for Neurodegenerative Diseases: Perspectives and Limitations
por: Fields, Matteo, et al.
Publicado: (2023)

Defibrotide impact on the acute GVHD disease incidence in pediatric hematopoietic stem cell transplant recipients
por: Squillaci, Domenica, et al.
Publicado: (2023)

Autoinflammatory Diseases and Cytokine Storms—Imbalances of Innate and Adaptative Immunity
por: Marcuzzi, Annalisa, et al.
Publicado: (2021)

P1272: DEFIBROTIDE IMPACT ON THE ACUTE GRAFT-VERSUS-HOST DISEASE INCIDENCE IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS.
por: Squillaci, Domenica, et al.
Publicado: (2023)

Acute Neurological Involvement after Donor Lymphocyte Infusion for Post-Transplant Viral Infection: The Same Pattern of Novel Cancer Immunotherapy-Related CNS Toxicity?
por: Marcuzzi, Annalisa, et al.
Publicado: (2022)

P1295: ADVANTAGE OF FIRST-LINE TDM-DRIVEN USE OF INFLIXIMAB FOR TREATING ACUTE INTESTINAL AND LIVER GVHD IN CHILDREN: A PROSPECTIVE, SINGLE-CENTER STUDY.
por: Maximova, Natalia, et al.
Publicado: (2023)

Post-Irradiation Hyperamylasemia Is a Prognostic Marker for Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in Pediatric Population: A Retrospective Single-Centre Cohort Analysis
por: Baldo, Francesco, et al.
Publicado: (2021)

Advantage of First-Line Therapeutic Drug Monitoring-Driven Use of Infliximab for Treating Acute Intestinal and Liver GVHD in Children: A Prospective, Single-Center Study
por: Maximova, Natalia, et al.
Publicado: (2023)

Mevalonate Kinase Deficiency and Squalene Synthase Inhibitor (TAK-475): The Balance to Extinguish the Inflammation
por: Rimondi, Erika, et al.
Publicado: (2021)

The impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseases
por: TÜRK, Can, et al.
Publicado: (2019)

MitoQ Is Able to Modulate Apoptosis and Inflammation
por: Piscianz, Elisa, et al.
Publicado: (2021)

Standard treatment–refractory cytomegalovirus encephalitis unmasked by immune reconstitution inflammatory syndrome and successfully treated with virus‐specific hyperimmune globulin
por: Maximova, Natalia, et al.
Publicado: (2020)

The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19
por: Goker Bagca, Bakiye, et al.
Publicado: (2020)

Role of vitamin D in the pathogenesis of atheromatosis
por: Rimondi, Erika, et al.
Publicado: (2021)

Prenylation Defects and Oxidative Stress Trigger the Main Consequences of Neuroinflammation Linked to Mevalonate Pathway Deregulation
por: Pisanti, Simona, et al.
Publicado: (2022)

Convolvulus pluricaulis Choisy’s Extraction, Chemical Characterization and Evaluation of the Potential Effects on Glycaemic Balance in a 3T3-L1 Adipocyte Cell Model
por: Melloni, Elisabetta, et al.
Publicado: (2023)

Editorial: Advances in stem cell therapy: new applications and innovative therapeutic approaches
por: Marcuzzi, Annalisa, et al.
Publicado: (2023)

Atomic Simulation of the Binding of JAK1 and JAK2 with the Selective Inhibitor Ruxolitinib
por: Kondratyev, Maxim, et al.
Publicado: (2022)

Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis
por: Keenan, Camille, et al.
Publicado: (2021)

Population Pharmacokinetics of Intravenous Acyclovir in Oncologic Pediatric Patients
por: Maximova, Natalia, et al.
Publicado: (2022)

Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration
por: Maximova, Natalia, et al.
Publicado: (2020)

Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib
por: Mascarenhas, J, et al.
Publicado: (2012)

The JAK1/2 inhibitor ruxolitinib delays premature aging phenotypes
por: Griveau, Audrey, et al.
Publicado: (2020)

Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
por: Smith, Paul, et al.
Publicado: (2021)

Levofloxacin Versus Ciprofloxacin-Based Prophylaxis during the Pre-Engraftment Phase in Allogeneic Hematopoietic Stem Cell Transplant Pediatric Recipients: A Single-Center Retrospective Matched Analysis
por: Servidio, Alessia G., et al.
Publicado: (2021)

Pentaglobin(®) Efficacy in Reducing the Incidence of Sepsis and Transplant-Related Mortality in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation: A Retrospective Study
por: Giorgia, Carlone, et al.
Publicado: (2020)

Ruxolitinib inhibits the proliferation and induces the apoptosis of MLL-r ALL cells through inactivating JAK/STAT signaling pathway
por: Liao, Xiong-Yu, et al.
Publicado: (2023)

Rapid Resolution of Life-Threatening Hypertriglyceridemia after Evinacumab Administration in a Pediatric HSCT Recipient: A Case Report
por: Fachin, Alice, et al.
Publicado: (2023)

Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib
por: Shide, K, et al.
Publicado: (2017)

The JAK inhibitor ruxolitinib abrogates immune hepatitis instigated by concanavalin A in mice
por: Shaker, Mohamed E., et al.
Publicado: (2022)

Ruxolitinib induces apoptosis of human colorectal cancer cells by downregulating the JAK1/2-STAT1-Mcl-1 axis
por: Li, Xia, et al.
Publicado: (2021)

Area-under-the-Curve-Based Mycophenolate Mofetil Dosage May Contribute to Decrease the Incidence of Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients
por: Carlone, Giorgia, et al.
Publicado: (2021)

Monocyte‐predominant engraftment, cytokine levels and early transplant‐related complications in pediatric hematopoietic stem cell recipients
por: Maximova, Natalia, et al.
Publicado: (2019)

The Dose Dependent Effects of Ruxolitinib on the Invasion and Tumorigenesis in Gliomas Cells via Inhibition of Interferon Gamma-Depended JAK/STAT Signaling Pathway
por: Delen, Emre, et al.
Publicado: (2020)

Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway
por: Chung, Shin-Yi, et al.
Publicado: (2021)

Parenteral Nutrition in the Pediatric Oncologic Population: Are There Any Sex Differences?
por: De Nardi, Laura, et al.
Publicado: (2023)

Pediatric males receiving hematopoietic stem cell transplant lose their male disadvantage in disease risk after the procedure: A retrospective observational study
por: De Nardi, Laura, et al.
Publicado: (2022)

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
por: Verstovsek, Srdan, et al.
Publicado: (2014)

A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma
por: Van Den Neste, Eric, et al.
Publicado: (2018)

P1428: IMPLICATIONS OF THE RUXOLITINIB (JAK1/JAK2 INHIBITOR) ON GRAFT-VERSUS-LEUKAEMIA EFFECT MEDIATED BY THE NK CELL.
por: Durán, C., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m6n0j75uc538bf9gf40le6jjlf